Orion Genomics (Orion)

Oncology Corporate Profile

HQ Location

4041 Forest Park Ave
St. Louis, MO 63108

Company Description

Orion Genomics develops oncology diagnostic products for cancer screening and therapy selection. Orion and its scientific founders have developed MethylScope® and MethylScreen® technologies, two powerful DNA methylation-based platforms, which scan the entire human genome to discover and validate novel cancer biomarkers.

Website: http://www.oriongenomics.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ODM-201androgen receptor inhibitorProstate cancerIII
Bladder Cancer Screen Testmolecular screening testBladder cancer BiomarkerDevelopment
Breast Cancer Screen Testmolecular screening testBreast cancer BiomarkerDevelopment
Orion Colorectal Cancer Risk Testepigenetic abnormality blood testColorectal cancer risk testDevelopment
Lung Cancer Screen Testmolecular screening testNon Small Cell Lung Cancer (NSCLC)Development
Prostate Cancer Screen Testmolecular screening testProstate cancer BiomarkerDevelopment

View additional information on product candidates here »

Source: http://www.oriongenomics.com/

Recent News Headlines

Bayer and Orion Expand Clinical Development Program for BAY-1841788 (ODM-201) in Prostate Cancer

6/3/2016 06:21 pm

(StreetInsider) June 3, 2016 - Phase III study to be initiated in metastatic hormone-sensitive prostate cancer assessing the androgen-receptor antagonist in combination with standard androgen deprivation therapy and the chemotherapy docetaxel; start of patient enrollment expected towards the end of 2016.

OncoGenex Announces Reduction in Force to Extend Cash Runway and Align Operations with Clinical Development Priorities

2/5/2016 12:03 pm

(Yahoo! Finance) Feb 4, 2016 - OncoGenex Pharmaceuticals, Inc. announced today that it is implementing a plan to reduce operating expenses, including a workforce reduction of approximately 27%.

Bayer and Orion Initiate Phase III Trial of Novel Prostate Cancer Agent ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

9/16/2014 12:12 pm

(Bayer HealthCare) Sept 16, 2014 - Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational novel oral androgen receptor (AR) inhibitor in clinical development for the treatment of patients with prostate cancer.

Bayer, Orion to Develop Novel Prostate Cancer Treatment

6/3/2014 12:07 am

(Drug Discovery & Development) June 2, 2014 - Bayer has entered into a global agreement with Orion Corp., a pharmaceutical company based in Espoo, Finland, for the development and commercialization of the compound ODM-201, an investigational novel oral androgen receptor inhibitor.

Bayer, Orion to Develop Novel Prostate Cancer Treatment

6/2/2014 02:00 pm

(Drug Discovery & Development) June 2, 2014 - Bayer has entered into a global agreement with Orion Corp., a pharmaceutical company based in Espoo, Finland, for the development and commercialization of the compound ODM-201, an investigational novel oral androgen receptor inhibitor.

When Doctors Sell Out, Hospitals Cash In

7/9/2013 11:04 am

(COA/Atlanta Journal-Constitution) July 8, 2013 - Everything was the same about Mike Rosenberg’s routine visit to Atlanta Cancer Care in February – everything, that is, but the bill.

Advances in Molecular Testing Offer New Hope for Lung Cancer Patients

4/4/2013 12:00 pm

(IASLC) Apr 3, 2013 - The emergence of molecular diagnostic testing in lung cancer offers new hope for patients battling the number one cancer killer in the United States and abroad.